Company news
Celldex Therapeutics, Inc. news in 2020
Celldex Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria
December 8, 2020
Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference
November 29, 2020
Celldex Presents Data from Oncology Portfolio at SITC 2020
November 8, 2020
Celldex Provides Corporate Update and Reports Third Quarter 2020 Results
November 4, 2020
Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria
October 12, 2020
Celldex Therapeutics to Present at Upcoming Healthcare Conferences
September 9, 2020
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors
August 23, 2020
Celldex Provides Corporate Update and Reports Second Quarter 2020 Results
August 5, 2020
Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call
August 2, 2020
Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 17, 2020
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock
June 14, 2020
Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile
June 5, 2020
Celldex Provides Corporate Update and Reports First Quarter 2020 Results
May 5, 2020
Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020
May 5, 2020
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
March 25, 2020
Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program
March 2, 2020